Comparative Pharmacology
Head-to-head clinical analysis: KELNOR versus TRI LO LINYAH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KELNOR versus TRI LO LINYAH.
KELNOR vs TRI-LO-LINYAH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combined oral contraceptive; inhibits ovulation by suppressing gonadotropin release (FSH and LH) primarily via progestational activity; increases viscosity of cervical mucus to inhibit sperm penetration; alters endometrium.
Combination estrogen-progestin oral contraceptive: suppresses gonadotropins (FSH and LH) via negative feedback, inhibiting ovulation; increases cervical mucus viscosity, reducing sperm penetration; alters endometrial structure, impairing implantation.
KELNOR (norethindrone acetate and ethinyl estradiol) is a combined oral contraceptive. Typical adult dose: 1 tablet (norethindrone acetate 1 mg/ethinyl estradiol 20 mcg) orally once daily for 21 days, followed by 7 placebo tablets, starting on day 1 of menstrual cycle.
One tablet orally once daily for 21 days, followed by 7 days of placebo. Each tablet contains 0.180 mg norgestimate and 0.025 mg ethinyl estradiol for days 1-7, 0.215 mg/0.025 mg for days 8-14, and 0.250 mg/0.025 mg for days 15-21.
None Documented
None Documented
Terminal elimination half-life 12-15 hours; clinically relevant for once-daily dosing.
Terminal elimination half-life: 12-15 hours; allows once-daily dosing but requires dose adjustment in renal impairment.
Primarily renal excretion of unchanged drug (70-80%) and glucuronide conjugate (10-15%); biliary/fecal elimination accounts for <5%.
Renal: ~60% as unchanged drug; fecal/biliary: ~40% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive